Publications by the researcher in collaboration with Rosario Palacios Muñoz (10)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118

2014

  1. Consensus document on the management of renal disease in HIV-infected patients

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

  2. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  3. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

2011

  1. Documento de Consenso del Grupo de Estudio del Sida (GESIDA)/Plan Nacional sobre el Sida (PNS) sobre las infecciones de transmisión sexual en pacientes con infección por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 4

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092